科学研究
学术报告
当前位置: 77779193永利集团 > 科学研究 > 学术报告 > 正文

Diabetes Prevention Program & its Outcome Study: A Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk

发布时间:2024-05-06 作者:77779193永利集团 浏览次数:
Speaker: PROF. QING PAN DateTime: 2024年5月21日(周二)下午16:00-17:00
Brief Introduction to Speaker:

Prof Pan got her PhD in Biostatistics from University of Michigan in 2007. She served as deputy chair of statistics at George Washington University in Washington DC, and is currently a full professor with tenure at the Department of Biostatistics & Bioinformatics, School of Public Health, GWU. She is also the co-director of the clinical & Population Core at DC CFAR (an HIV research center). She has been PI and co-I/lead statistician in many US NIH, Gates Foundation, FDA, Department of Justice projects with over 70 publications. She served in many US and international review panels, program committees and editorial boards. She won the Gertrude M. Cox award from the American Statistical Association in 2022.



Place: 6号楼2楼报告厅
Abstract:There is a long period of glucose intolerance that precedes the development of diabetes. Screening tests can identify persons at high risk. Furthermore, there are safe, potentially effective interventions that can address modifiable risk factors such as obesity, body fat distribution, physical inactivity and elevated fasting and 2hr glucose. The Diabetes Prevention Program (DPP) compares Intensive Lifestyle Training (ILS), Metformin (MET) and Placebo (PLA) on reducing the risks of Type 2 Diabetes (T2D) in people with impaired glucose tolerance. In total, 3234 participants were recruited across all 27 clinical sites and have been followed since 1996. 58% and 31% risk reduction have been observed in the ILS and MET groups, respectively, during the randomized stage. Both treatment options are safe and effective across all age, gender, race groups. After 2002, all participants received modified ILS for ethical reasons. Reduced risks of microvascular complications (nephropathy, retinopat...